Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to -$432000.0.

  • Cartesian Therapeutics' Change in Accured Expenses fell 17297.3% to -$432000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.5 million, marking a year-over-year increase of 6140.47%. This contributed to the annual value of -$6.7 million for FY2024, which is 14415.07% down from last year.
  • Latest data reveals that Cartesian Therapeutics reported Change in Accured Expenses of -$432000.0 as of Q3 2025, which was down 17297.3% from -$2.0 million recorded in Q2 2025.
  • Cartesian Therapeutics' Change in Accured Expenses' 5-year high stood at $3.2 million during Q2 2022, with a 5-year trough of -$6.4 million in Q1 2024.
  • In the last 5 years, Cartesian Therapeutics' Change in Accured Expenses had a median value of -$432000.0 in 2025 and averaged -$572421.1.
  • Per our database at Business Quant, Cartesian Therapeutics' Change in Accured Expenses soared by 71666.67% in 2023 and then plummeted by 22277.58% in 2024.
  • Quarter analysis of 5 years shows Cartesian Therapeutics' Change in Accured Expenses stood at -$679000.0 in 2021, then skyrocketed by 332.25% to $1.6 million in 2022, then crashed by 171.21% to -$1.1 million in 2023, then soared by 203.56% to $1.2 million in 2024, then plummeted by 137.15% to -$432000.0 in 2025.
  • Its last three reported values are -$432000.0 in Q3 2025, -$2.0 million for Q2 2025, and -$2.2 million during Q1 2025.